AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26481811 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (60 μg/d)
Number of subjects: 230
Study 26481811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 25395311 — intervention group
Group type: EXPERIMENTAL
Intervention: IBUNa 2 × 256 mg
Number of subjects: 71
Study 25395311 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 71
Study 22526014 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg administered intravenously prior to surgery
Number of subjects: 34
Study 19660338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia
Number of subjects: 80
Study 19660338 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 80
Study 19017409 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion (n = 16)
Number of subjects: 32
Study 19017409 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (n = 16)
Number of subjects: 32
Study 16895622 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 1 mg kg(‐1)
Number of subjects: 90
Study 16895622 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline 2 mg kg(‐1)
Number of subjects: 90
Study 16895622 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo intravenous
Number of subjects: 90
Study 12752836 — intervention group
Group type: EXPERIMENTAL
Intervention: Very unsteady patients at admission
Number of subjects: 1557
Study 12752836 — intervention group
Group type: COMPARATOR
Intervention: Slightly unsteady patients at admission
Number of subjects: 1557
Study 12752836 — intervention group
Group type: COMPARATOR
Intervention: Slightly steady patients at admission
Number of subjects: 1557
Study 12752836 — intervention group
Group type: COMPARATOR
Intervention: Very steady patients at admission
Number of subjects: 1557
Study 12752836 — intervention group
Group type: EXPERIMENTAL
Intervention: Very unsteady patients who declined before hospitalization
Number of subjects: 1557
Study 12752836 — intervention group
Group type: COMPARATOR
Intervention: Slightly unsteady patients who declined before hospitalization
Number of subjects: 1557
Study 12752836 — intervention group
Group type: COMPARATOR
Intervention: Slightly steady patients who declined before hospitalization
Number of subjects: 1557
Study 12752836 — intervention group
Group type: COMPARATOR
Intervention: Very steady patients who declined before hospitalization
Number of subjects: 1557
Study 10845343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) group intervention for 10 weeks
Number of subjects: 34
Study 10845343 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 34
Study 8979659 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.25 percent with silicone punctal plugs
Number of subjects: 17
Study 8979659 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.25 percent without silicone punctal plugs
Number of subjects: 17
Study 1607083 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via oral route (2 liters/min)
Number of subjects: 0
Study 1607083 — intervention group
Group type: COMPARATOR
Intervention: Supplemental oxygen via nasal cannulas (2 liters/min)
Number of subjects: 0
Study 1607083 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-oxygenation
Number of subjects: 0
Study 1607083 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (2 liters/min)
Number of subjects: 0
Study 2411649 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 488
Study 2411649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 488
Study 30307129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-mm implants
Number of subjects: 11
Study 30307129 — intervention group
Group type: COMPARATOR
Intervention: 10 or 8-mm long implants
Number of subjects: 11
Study 30307129 — intervention group
Group type: COMPARATOR
Intervention: Long implants in augmented bone
Number of subjects: 11
Study 26721935 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldelumab 25 mg/kg
Number of subjects: 252
Study 26721935 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldelumab 15 mg/kg
Number of subjects: 252
Study 26721935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 25041577 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral migraine management (BMM)
Number of subjects: 232
Study 25041577 — intervention group
Group type: COMPARATOR
Intervention: Beta-blocker
Number of subjects: 232
Study 22060048 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation surgery
Number of subjects: 35
Study 22060048 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented control sinuses
Number of subjects: 35
Study 20594588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycaemia control (target HbA(1c) <6.0%)
Number of subjects: 10251
Study 20594588 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemia control (target HbA(1c) 7.0-7.9%)
Number of subjects: 10251
Study 20594588 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary measures favoring intensive therapy
Number of subjects: 10251
Study 18854722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg by mouth per day)
Number of subjects: 26
Study 18854722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16269081 — intervention group
Group type: EXPERIMENTAL
Intervention: ANCOVA
Number of subjects: 0
Study 16269081 — intervention group
Group type: EXPERIMENTAL
Intervention: Mann‐Whitney
Number of subjects: 0
Study 12242602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg for 2 days, then 30 mg for 5 days) plus phenytoin (200 mg daily for 17 days)
Number of subjects: 17
Study 12242602 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (200 mg daily from day 8 to day 17) plus mirtazapine (15 mg for 2 days, then 30 mg for 15 days)
Number of subjects: 17
Study 12242602 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (200 mg daily)
Number of subjects: 17
Study 10080828 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIFN-gamma injections paired with PG
Number of subjects: 31
Study 10080828 — intervention group
Group type: COMPARATOR
Intervention: normal saline injections paired with PG
Number of subjects: 31
Study 10080828 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIFN-gamma injections alone
Number of subjects: 31
Study 7653318 — intervention group
Group type: COMPARATOR
Intervention: 2 mg nicotine gum (0 pieces per day)
Number of subjects: 177
Study 7653318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (7 pieces per day)
Number of subjects: 177
Study 7653318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (15 pieces per day)
Number of subjects: 177
Study 7653318 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum (30 pieces per day)
Number of subjects: 177
Study 7653318 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cotinine levels (high and low)
Number of subjects: 177
Study 7653318 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal symptoms
Number of subjects: 177
Study 2344503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 1.25 mg
Number of subjects: 257
Study 2344503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg
Number of subjects: 257
Study 2344503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 257
Study 2344503 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 10 mg
Number of subjects: 257
Study 2344503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 344341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofluorescence‐nDNA antibody test system
Number of subjects: 236
Study 344341 — intervention group
Group type: COMPARATOR
Intervention: Radioimmunoassay procedure (FARR assay)
Number of subjects: 236
Study 30475668 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8010
Study 30475668 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8010
Study 28934837 — intervention group
Group type: EXPERIMENTAL
Intervention: 1W bromocriptine treatment (2.5 mg for 7 days)
Number of subjects: 63
Study 28934837 — intervention group
Group type: EXPERIMENTAL
Intervention: 8W bromocriptine treatment (5 mg for 2 weeks followed by 2.5 mg for 6 weeks)
Number of subjects: 63
Study 28934837 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with bromocriptine)
Number of subjects: 63
Study 28934837 — intervention group
Group type: EXPERIMENTAL
Intervention: 1W bromocriptine treatment
Number of subjects: 63
Study 28934837 — intervention group
Group type: EXPERIMENTAL
Intervention: 8W bromocriptine treatment
Number of subjects: 63
Study 25238025 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE) 100, 250, 500 or 1000 mg once daily or 250 mg twice daily
Number of subjects: 252
Study 25238025 — intervention group
Group type: EXPERIMENTAL
Intervention: Remogliflozin etabonate (RE)
Number of subjects: 252
Study 25238025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 25238025 — intervention group
Group type: COMPARATOR
Intervention: 30 mg pioglitazone once daily
Number of subjects: 252
Study 23169690 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 140
Study 23169690 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 140
Study 20878572 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy every two weeks in each cycle
Number of subjects: 78
Study 20878572 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with FOLFOX4 regimen neoadjuvant chemotherapy
Number of subjects: 78
Study 20878572 — intervention group
Group type: COMPARATOR
Intervention: Control group received surgery within 2 weeks and postoperative chemotherapy of 6 cycles of paclitaxel combined with FOLFOX4 regimen
Number of subjects: 78
Study 20878572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 78
Study 18436088 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention for family physicians (6 months duration)
Number of subjects: 94
Study 16905888 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological training
Number of subjects: 118
Study 16905888 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity training
Number of subjects: 118
Study 16905888 — intervention group
Group type: COMPARATOR
Intervention: Both training groups
Number of subjects: 118
Study 12802023 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg weekly injections
Number of subjects: 463
Study 12802023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert oil) weekly injections
Number of subjects: 463
Study 10844868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1H‐MRS
Number of subjects: 14
Study 8888419 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise with X1000 Walk'N Tone Exercise Belt
Number of subjects: 18
Study 8888419 — intervention group
Group type: EXPERIMENTAL
Intervention: Land exercise with X1000 Walk'N Tone Exercise Belt
Number of subjects: 18
Study 8888419 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exercise without X1000 Walk'N Tone Exercise Belt
Number of subjects: 18
Study 8888419 — intervention group
Group type: EXPERIMENTAL
Intervention: Land exercise without X1000 Walk'N Tone Exercise Belt
Number of subjects: 18
Study 1891485 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (1.48 mg daily)
Number of subjects: 62
Study 1891485 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (44.4 mg daily)
Number of subjects: 62
Study 6576616 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (one-hour weekly sessions for a maximum of ten sessions)
Number of subjects: 103
Study 6576616 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only (control group)
Number of subjects: 103
Study 30198775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron isomaltoside (IVI)
Number of subjects: 27
Study 30198775 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 27
Study 28453197 — intervention group
Group type: EXPERIMENTAL
Intervention: Peers present during the Iowa Gambling Task (IGT)
Number of subjects: 101
Study 28453197 — intervention group
Group type: COMPARATOR
Intervention: Alone during the Iowa Gambling Task (IGT)
Number of subjects: 101
Study 24548816 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) during diaper change
Number of subjects: 19
Study 24548816 — intervention group
Group type: COMPARATOR
Intervention: Diaper change in incubator/bed with mother present
Number of subjects: 19
Study 23222818 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone/Everolimus (P/EVL)
Number of subjects: 26
Study 23222818 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone/Cyclosporine A (P/CsA)
Number of subjects: 26
Study 23222818 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone/Mycophenolate Sodium (P/MPS)
Number of subjects: 26
Study 23222818 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (mTOR inhibitor)
Number of subjects: 26
Study 21615576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education programme (experimental group)
Number of subjects: 122
Study 21615576 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 122
Study 17680591 — intervention group
Group type: EXPERIMENTAL
Intervention: Shapesville
Number of subjects: 84
Study 17680591 — intervention group
Group type: COMPARATOR
Intervention: Control book
Number of subjects: 84
Study 17157730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical shaving plus monopolar radiofrequency (MRF)
Number of subjects: 60
Study 17157730 — intervention group
Group type: COMPARATOR
Intervention: Mechanical shaving alone
Number of subjects: 60
Study 14587684 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica D30
Number of subjects: 82
Study 14587684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 11025241 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-N2O
Number of subjects: 62
Study 11025241 — intervention group
Group type: COMPARATOR
Intervention: Propofol for induction and isoflurane-N2O for maintenance (Control)
Number of subjects: 62
Study 8988412 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), 100 mg capsules or 10% fine granules, given orally
Number of subjects: 27
Study 8988412 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), 8.3 mg/kg once daily for 3 days
Number of subjects: 27
Study 8988412 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), 12.5 mg/kg once daily for 3 days
Number of subjects: 27
Study 8988412 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety evaluation of Azithromycin (AZM)
Number of subjects: 27
Study 1617930 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (ROX) 150 mg b.i.d. orally (n = 244)
Number of subjects: 490
Study 1617930 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin plus clavulanic acid (AMX + CA) 500 mg AMX + 125 mg CA t.i.d. orally (n = 246)
Number of subjects: 490
Study 1617930 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin plus clavulanic acid (AMX + CA)
Number of subjects: 490
Study 1617930 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin (ROX)
Number of subjects: 490
Study 6398125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin plus amoxicillin (CFL)
Number of subjects: 73
Study 6398125 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin
Number of subjects: 73
Study 30084900 — intervention group
Group type: EXPERIMENTAL
Intervention: SKN2017B
Number of subjects: 45
Study 30084900 — intervention group
Group type: COMPARATOR
Intervention: Silicone cream
Number of subjects: 45
Study 28988493 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text message feedback from a parent, peer, or behavioral health specialist
Number of subjects: 10
Study 28988493 — intervention group
Group type: COMPARATOR
Intervention: No text message (control)
Number of subjects: 10
Study 26308179 — intervention group
Group type: EXPERIMENTAL
Intervention: Carn‐BA (2 g of L‐carnosine and 2 g of β‐alanine)
Number of subjects: 12
Study 26308179 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 12
Study 24628890 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo lung perfusion (EVLP)
Number of subjects: 35
Study 22684197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Muscular Stabilization Technique (DMST)
Number of subjects: 72
Study 19933530 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation (AUS)
Number of subjects: 80
Study 19933530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighted Stylet (LS)
Number of subjects: 80
Study 19933530 — intervention group
Group type: COMPARATOR
Intervention: Manufacturer‐Recommended (MR)
Number of subjects: 80
Study 19933530 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Bronchoscope (FOB)
Number of subjects: 80
Study 17870126 — intervention group
Group type: EXPERIMENTAL
Intervention: Core learning objectives curriculum
Number of subjects: 20
Study 17870126 — intervention group
Group type: COMPARATOR
Intervention: Traditional curricula
Number of subjects: 20
Study 16365694 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with closed mouth and 25 mm open mouth
Number of subjects: 16
Study 16365694 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with closed mouth
Number of subjects: 16
Study 16365694 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with 25 mm open mouth
Number of subjects: 16
Study 16365694 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI with 5 mm open mouth
Number of subjects: 16
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis for spontaneous bacterial peritonitis
Number of subjects: 35
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant dialysis
Number of subjects: 35
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: Retransplantation
Number of subjects: 35
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: C. albicans infections
Number of subjects: 35
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases (invasive candidiasis)
Number of subjects: 35
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-albicans Candida infections
Number of subjects: 35
Study 12829905 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior antifungal prophylaxis
Number of subjects: 35
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: tiopronin (200 mg/day) for 14 days
Number of subjects: 100
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: tiopronin (500 mg/day) for 14 days
Number of subjects: 100
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (5 mg/day) for 14 days
Number of subjects: 100
Study 11214766 — intervention group
Group type: COMPARATOR
Intervention: conservative measures (no medication)
Number of subjects: 100
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: tiopronin (200 mg/day)
Number of subjects: 100
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: tiopronin (500 mg/day)
Number of subjects: 100
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine (5 mg/day)
Number of subjects: 100
Study 11214766 — intervention group
Group type: EXPERIMENTAL
Intervention: tiopronin (200 mg/day) and bromocriptine
Number of subjects: 100
Study 8878196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's anesthesia
Number of subjects: 106
Study 8878196 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 106
Study 1670746 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (11.9 +/- 0.9 mg daily)
Number of subjects: 73
Study 1670746 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 73
Study 1670746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 6408068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion plus haloperidol
Number of subjects: 20
Study 6408068 — intervention group
Group type: COMPARATOR
Intervention: Bupropion alone
Number of subjects: 20
Study 31618617 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity-score matching
Number of subjects: 0
Study 31618617 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 30698554 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognan (citicoline) 500 mg (5 ml) orally for 30 days
Number of subjects: 58
Study 30698554 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug therapy)
Number of subjects: 58
Study 26690861 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Personal Administration of Cognitive Therapy (ePACT)
Number of subjects: 48
Study 26690861 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 48
Study 26690861 — intervention group
Group type: EXPERIMENTAL
Intervention: Small subgroup reinterviewed at Time 3 (n=12)
Number of subjects: 48
Study 24668203 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral extracranial-intracranial direct bypass
Number of subjects: 80
Study 24668203 — intervention group
Group type: COMPARATOR
Intervention: Conservative care (nonsurgical)
Number of subjects: 80
Study 22424000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose, insulin, and potassium (GIK) administered prehospital by paramedics
Number of subjects: 911
Study 22424000 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered prehospital by paramedics
Number of subjects: 911
Study 19950043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acclimatisation protocol (faster ascent)
Number of subjects: 34
Study 19950043 — intervention group
Group type: COMPARATOR
Intervention: Acclimatisation protocol (slower ascent)
Number of subjects: 34
Study 19950043 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude increase (up to 6865 m)
Number of subjects: 34
Study 19950043 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention
Number of subjects: 34